展望未来：慢性乙型肝炎的新型药物
Looking to the future: new agents for chronic hepatitis B.
作者信息
Dienstag Jules L
机构信息
Massachusetts General Hospital, Harvard Medical School, Blake 4, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Am J Gastroenterol. 2006;101 Suppl 1:S19-25. doi: 10.1111/j.1572-0241.2006.00377.x.
New antiviral agents are currently being developed to treat patients with chronic hepatitis B. Both pegylated interferon alfa-2a and entecavir are now approved for the treatment of hepatitis B while telbivudine, tenofovir, emtricitabine, and pegylated interferon alfa-2b are in clinical development. Successive advances have resulted in more profound suppression of hepatitis B replication, a reduction in breakthrough resistance, and an increase in the frequency of attainment of virologic, serologic, biochemical, and histologic clinical endpoints.
目前正在研发新型抗病毒药物来治疗慢性乙型肝炎患者。聚乙二醇化干扰素α-2a和恩替卡韦现已获批用于治疗乙型肝炎，而替比夫定、替诺福韦、恩曲他滨和聚乙二醇化干扰素α-2b正处于临床研发阶段。一系列进展已实现对乙型肝炎病毒复制更有效的抑制、突破性耐药的减少以及病毒学、血清学、生化和组织学临床终点达标率的提高。
Zotero 插件